Approved Indications for Use (Europe & Canada)

The autoRIC® Device is intended to provide remote ischemic conditioning to adult patients over 18 years of age undergoing cardiothoracic surgery or interventional cardiothoracic procedures or patients with evolving myocardial infarction.
The autoRIC® Device is intended for use in the hospital setting, ambulance setting or in a home setting as directed by a healthcare professional.
CAUTION: Investigational Device. Limited by United States law to Investigational Use.

The autoRIC® Device

Patented Technology
Automated and Non-invasive

Delivers Remote Ischemic Conditioning (RIC) to the patient through a non-invasive and automated application. The autoRIC® Device is highly portable and time‐efficient, delivering four cycles of simple‐to-administer treatment in less than 40 minutes, freeing up valuable healthcare resources. Device operation is simple and compatible with current standard‐of‐care treatments. RIC delivery is consistent, reliable, and cost-effective.

Spectrum of Care
Automating RIC Across the Spectrum of Care

CellAegis’ autoRIC® Device can be used across the spectrum of care: RIC has proven efficacy in acute care settings, including treatment of patients in the ambulance or emergency room, or before Cath Lab procedures or other cardiac interventions. The simple to use autoRIC® Device also allows for patient administered treatment in the home for chronic disease treatment.


Learn more about the RIC Spectrum of Care


Patented Technology

The autoRIC® Device is the only commercially available and regulatory approved, proprietary device which automates the delivery of RIC with CE Mark certification in Europe and Health Canada approval. The autoRIC® Device is limited by US law to investigational use only.

Approved Indications for Use (Europe & Canada)
The autoRIC® Device is intended to provide remote ischemic conditioning to adult patients over 18 years of age undergoing cardiothoracic surgery or interventional cardiothoracic procedures or patients with evolving myocardial infarction.

For more information about the autoRIC® Device or to inquire about our Canadian or European Hospital Early Adopter Program...

Call us: 1-647-722-9601
Email us: info@cellaegisdevices.com

The autoRIC® Device Patents & Trademarks

CRICtrac™ Mobile App

CRICtrac™ Mobile App

Simplify Your Chronic RIC Clinical Trial Using CRICtrac™

The autoRIC® Device and CRICtrac™ Mobile App are the solution for clinicians looking to provide chronic RIC (CRIC) for their patients without the concerns of being able to verify compliance with the treatment. Combining the autoRIC® Device’s reliability in delivering RIC Therapy with the CRICtrac™ Mobile App, allows the clinician to provide, to the patient, self-delivered CRIC therapy in the home setting, without the cost or burden of a daily nurse home visit. Not only does it provide you with the information you need to determine individual patient compliance, it also generates the report needed to better understand patient compliance behavior and assist in interpreting trial data.

For more information about the CRICtrac™ Mobile App...

Call us: 1-647-722-9601
Fax us: 1-647-722-9553
Email us: clinical@cellaegisdevices.com